Cost-Effectiveness and Net Monetary Benefit of olaparib Maintenance Therapy Versus No Maintenance Therapy After First-Line Platinum-Based Chemotherapy in Newly Diagnosed Advanced BRCA1/2-Mutated Ovarian Cancer in the Italian National Health Service
Global cancer observatory (GCO).
()
2019
Diagnosis and management of ovarian cancer.
Am Fam Physician. 2016; 93: 937-944
High-grade serous ovarian cancer: basic sciences, clinical and therapeutic standpoints.
Int J Mol Sci. 2019; 20: 952
Recent progress in the diagnosis and treatment of ovarian cancer.
CA Canc J Clin. 2011; 61: 183-203
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer.
Nat Rev Canc. 2015; 15: 668-679
Association of BRCA1/2 mutations with ovarian cancer prognosis: an updated meta-analysis.
Medicine (Baltimore). 2018; 97: e9380
BRCA mutation in ovarian cancer: testing, implications and treatment considerations.
Ther Adv Med Oncol. 2017; 9: 519-531
Epidemiology of patients with ovarian cancer with and without a BRCA1/2 mutation.
Mol Diagn Ther. 2015; 19: 351-364
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease dagger.
Ann Oncol. 2019; 30: 672-705
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Ann Oncol. 2013; 24: vi24-vi32
Incorporation of bevacizumab in the primary treatment of ovarian cancer.
N Engl J Med. 2011; 365: 2473-2483
Final overall survival of a randomized trial of bevacizumab for primary treatment of ovarian cancer.
J Clin Oncol. 2019; 37: 2317-2328
Rucaparib Maintenance Treatment for Recurrent Ovarian Carcinoma after Response to Platinum Therapy (ARIEL3): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial.
390. Lancet,
London, England)2017: 1949-1961
Niraparib maintenance therapy in platinum-sensitive, recurrent ovarian cancer.
N Engl J Med. 2016; 375: 2154-2164
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2017; 18: 1274-1284
ClinicalTrials.gov. Olaparib Maintenance Monotherapy in Patients with BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy (SOLO-1) https://clinicaltrials.gov/ct2/show/NCT01844986. Last accessed: May 18, 2020.
Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer.
N Engl J Med. 2018; 379: 2495-2505
FDA Approved Olaparib (LYNPARZA, AstraZeneca Pharmaceuticals LP) for the Maintenance Treatment of Adult Patients with Deleterious or Suspected Deleterious Germline or Somatic BRCA-Mutated (gBRCAm or sBRCAm) Advanced Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer Who Are in Complete or Partial Response to First-Line Platinum-Based.
()19 December 2018
Summary of Opinion (Post Authorisation).
()28 February 2019
Front-line therapy of advanced ovarian cancer: new approaches.
28. Ann Oncol,
2017: viii46-viii50
Country-level Cost-Effectiveness Thresholds: Initial Estimates and the Need for Further Research.
CHE Research Paper,
2016: 109
TreeAge Pro 2019, R2.
()
Linee Guida – Tumori Dell’ovaio.
2018
Ovarian cancer.
Ann Oncol. 2016; 27 () (): v145
OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer.
J Clin Oncol. 2012; 30: 2039-2045
Olaparib for Maintenance Treatment of BRCA-Mutated Ovarian, Fallopian Tube and Peritoneal Cancer after Response to First-Line Platinum-Based Chemotherapy [ID1124].
2019
Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies.
Drug Info J. 2001; 35: 189-201
Plot Digitizer.
()
Reconstructing time-to-event data from published Kaplan-Meier curves.
Stata J. 2017; 17: 786-802
Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves.
BMC Med Res Methodol. 2012; 12: 9
Survival modeling for the estimation of transition probabilities in model-based economic evaluations in the absence of individual patient data: a tutorial.
Pharmacoeconomics. 2014; 32: 101-108
NICE DSU technical support document 14: survival analysis for economic evaluations alongside clinical trials—extrapolation with patient-level data.
()
Characteristics of long-term survivors of epithelial ovarian cancer.
Obstet Gynecol. 2015; 126: 491-497
The road to long-term survival: surgical approach and longitudinal treatments of long-term survivors of advanced-stage serous ovarian cancer.
Gynecol Oncol. 2019; 152: 228-234
Tavole di mortalità della popolazione residente.
()2019
Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
J Clin Oncol. 2012; 30: 3841-3847
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer.
J Clin Oncol. 2008; 26: 890-896
Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.
J Clin Oncol. 2010; 28: 3107-3114
Bevacizumab or PARP-inhibitors maintenance therapy for platinum-sensitive (PS) recurrent ovarian cancer (rOC)? A network meta-analysis (NMA).
J Clin Oncol. 2019; 37: 5564
Bevacizumab in Combination with Gemcitabine and Carboplatin for Treating the First Recurrence of Platinum-Sensitive Advanced Ovarian Cancer.
2013
Rucaparib for Maintenance Treatment of Relapsed Platinum-Sensitive Ovarian, Fallopian Tube or Peritoneal Cancer [ID1485].
2019
Riclassificazione del medicinale per uso umano «Lynparza» ai sensi dell’articolo 8, comma 10, della legge 24 dicembre 1993.
()n. 537. 2019
Regime di rimborsabilita’ e prezzo di vendita del medicinale «Yondelis (trabectedina)» – autorizzata con procedura centralizzata europea dalla Commissione europea.
2009 ()
Regime di rimborsabilita’ e prezzo a seguito di nuove indicazioni terapeutiche del medicinale «Caelyx» (doxorubicina cloridrato liposomiale pegilata).
2009 ()
Regime di rimborsabilita’ e prezzo a seguito di nuove indicazioni terapeutiche del medicinale per uso umano «Avastin».
2016 ()
Regime di rimborsabilita’ e prezzo del medicinale per uso umano «Zejula».
2018 ()
Riclassificazione del medicinale per uso umano «Rubraca» ai sensi dell’art. 8, comma 10, della legge 24 dicembre 1993.
n. 537. 2019 ()
Italian Medicines Agency (AIFA), Elenchi farmaci di classe A e H.
Cost-effectiveness of niraparib versus routine surveillance, olaparib and rucaparib for the maintenance treatment of patients with ovarian cancer in the United States.
Pharmacoeconomics. 2019; 37: 391-405
Decreto del Ministero della salute 18 ottobre 2012, allegato 1, “Tariffe delle prestazioni di assistenza ospedaliera per acuti, per tipo di ricovero.
()
Palliative care treatment patterns and associated costs of healthcare resource use for specific advanced cancer patients in the UK.
Eur J Canc Care (Engl). 2006; 15: 65-73
Economic burden of patients affected by non-small cell lung cancer (NSCLC): the LIFE study.
J Canc Res Clin Oncol. 2017; 143: 783-791
Niraparib for Maintenance Treatment of Relapsed, Platinum-Sensitive Ovarian, Fallopian Tube and Peritoneal Cancer [ID1041].
2018
Olaparib for Maintenance Treatment of Relapsed, Platinum-Sensitive, BRCA Mutation-Positive Ovarian, Fallopian Tube and Peritoneal Cancer after Response to Second-Line or Subsequent Platinum-Based Chemotherapy [ID735].
2016
Nomenclatore dell’assistenza specialistica ambulatoriale.
()
Comments are closed.